All News
Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 https://t.co/5ygHgOTfW8
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs
- Fast onset
- High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9
Eric Dein ericdeinmd ( View Tweet)
"We are setting a new standard for the skin, PASI100" -Dr. A Armstrong on the goal of treatment for #psoriasis. #TigerMom @rheumnow #RNL2024
TheDaoIndex KDAO2011 ( View Tweet)
In a patient with purely skin limited plaque psoriasis without systemic involvement, what would you choose for treatment? The rheum audience poll at #RNL2024 is all over the place in their choice! Dr. Armstrong lectures on how derms think about #psoriasis @rheumnow https://t.co/4YxaJPlpa5
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Choosing a biologic in Psoriasis
TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B
IL-17 - robust skin, PsA (axial too). Avoid in IBD
IL-23 - robust skin, PsA evidence, fewer injections https://t.co/9Xt7Nx1tKq
Eric Dein ericdeinmd ( View Tweet)
Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow https://t.co/4AtbEhysyA
Dr. Rachel Tate uptoTate ( View Tweet)
Derms are thinking like rheums now!
Dr. April Armstrong noted most derms digging below the surface to assess pts with psoriasis for systemic diseases to help them to choose systemic treatments. @rheumnow #RNL2024 https://t.co/7HTmiA6m4L
TheDaoIndex KDAO2011 ( View Tweet)
EULAR guidelines and GRAPPA guidelines are moving closer to each other in treatment approaches - @AlexisOgdie @rheumnow #RNL2024 https://t.co/wtp57s28Bz
TheDaoIndex KDAO2011 ( View Tweet)
EULAR 2019 PsA treatment guidelines, as detailed in 2023 presented by @AlexisOgdie
We are starting to see EULAR and GRAPPA guidelines complimenting each other with the caveat that EULAR tends to focus on oligo vs polyarticular, vs peripheral arthritis terminology in GRAPPA… https://t.co/K8gtI7Makm https://t.co/iK5x8hlIda
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Effects of obesity and weight loss in PsA. Very significant benefit, OR of MDA 6.67 for 10%+ weight loss @AlexisOgdie @RheumNow #RNL2024 https://t.co/130KAucPl7
Richard Conway RichardPAConway ( View Tweet)
GRAPPA recommendations 2021
Guide therapy by the active domains, filter by co-morbidities
@AlexisOgdie @RheumNow
#RNL2024 https://t.co/C1RQAM8DrI
Eric Dein ericdeinmd ( View Tweet)
Dr. @AlexisOgdie reviews the updated GRAPPA guideline and changes since 2015. #RNL2024 @RheumNow https://t.co/N2HAmlLj83
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
"In patients with IBD, don't treat with drugs that don't work in IBD." @alexisogdie on why common sense should prevail @rheumnow #RNL2024
TheDaoIndex KDAO2011 ( View Tweet)
How to define "severe" disease? Erosions, multi-site involvement, affecting ADLs/QoL - @AlexisOgdie @rheumnow #RNL2024 https://t.co/gc8bSeSTyJ
TheDaoIndex KDAO2011 ( View Tweet)
2018 ACR/National Psoarasis Foundation Guidelines for Treatment of PsA
- Created helpful definitions of Severe PsA and Severe PsO
#RNL2024 @RheumNow @AlexisOgdie https://t.co/kH4UzlEWxA
Eric Dein ericdeinmd ( View Tweet)
Clinical pearl alert!
Check out https://t.co/rvkKlJ8mtk.
This site can help you with your PsO decision tree and will be updated again this year.
@AlexisOgdie also shares her personal decision tree when approaching patient care while emphasizing shared decision making.
#RNL2024… https://t.co/GFYjHw2hgF https://t.co/I8xpekFmYk
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
“TNFi, IL17i, JAKi--- note that these are the only classes of drug that work for axial spondyloarthritis!” – Dr.
@AlexisOgdie noted ustekinumab, apremilast, and abatacept do not work for inflammatory back pain.
@rheumnow #RLN2024 https://t.co/BHV6qCUdYi
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@AlexisOgdie
Many therapies for SpA - but ONLY TNFi, IL17i, and JAKi for AxSpA
Check out https://t.co/V7JGc6t72C to help guide treatment decisions: Prior therapies? enthesitis? concomitant IBD/uveitis? comorbidities? Pt preferences? https://t.co/hfFikMs9YL
Links:
Eric Dein ericdeinmd ( View Tweet)
Thinking of joint, skin, axial disease in psoriatic arthritis and extra-articular manifestations leading to shared decision making, Alexis Ogdie #RNL2024 @RheumNow https://t.co/F57sEicht7
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)